This article is more than 5 years old. Information may no longer be current.

Adverum, Editas extend research collaboration

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Adverum Biotechnologies and Editas Medicine have extended their collaboration agreement to explore the delivery of genome editing medicines to treat inherited retinal diseases, Adverum announced in a press release.

The companies are extending the research period through the third quarter of 2018, and Editas has a series of options exercisable between now and August 2020, the release said.

The collaboration focuses on utilizing Adverum’s adeno-associated viral vectors to deliver Editas’ CRISPR-based genome editing technologies in order to develop therapies for eye diseases, according to Amber Salzman, PhD, Adverum’s president and CEO.